A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals' launch of a generic version of Novartis' blockbuster heart-failure drug Entresto late on Wednesday. The U.S. Court of Appeals for the District of Columbia Circuit halted the launch, which could have begun as early as Thursday, while it considers Novartis' emergency request for a longer pause. A separate ruling on Wednesday from U.S. District Judge Dabney Friedrich in Washington had cleared a hurdle for MSN to introduce the first U.S. generic of Switzerland-based Novartis' best-selling drug, which brought the company more than $6 billion in revenue in 2023.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
